N@N

Matthew Harrison Maintained (SRPT) at Hold with Increased Target to $141 on, Oct 13th, 2022

Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $135 to $141 on, Oct 13th, 2022.

Matthew has made no other calls on SRPT in the last 4 months.

There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $93 on, Wednesday, August 3rd, 2022

These are the ratings of the 4 analyists that currently disagree with Matthew

---

• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $124 on, Thursday, August 18th, 2022
• Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $182 on, Tuesday, August 9th, 2022
• Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $162 on, Friday, July 29th, 2022
• Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022

Contributing Sources

---